PT-141 (bremelanotide)
FDA-approved for low desire in premenopausal women. A small effect, lots of nausea.
Grade A: Strong human proof
Big trials in people, and it worked.
The grade is for the use people talk about, not for every use. Filed under: Libido and sex hormones.
How it works
Switches on melanocortin receptors in the brain that are involved in sexual desire.
How it was given in studies
Injection under the skin, in the approval trials in women and on the FDA label. An earlier trial in men used a nasal spray.
This is what the studies did. It is not a how-to. Source: Two trials in women. Obstetrics and Gynecology, 2019; Trial in 342 men. Journal of Urology, 2008; FDA label on DailyMed.
What studies saw
Two 24-week trials in 1,267 premenopausal women with low desire found a small but real improvement in desire scores over placebo, and less distress. In one trial of 342 men who had not responded to sildenafil, a nasal spray version helped about 34%, against 9% on placebo.
The trade-off
On the label, nausea hit 40% of women, against 1% on placebo. Blood pressure rises for a few hours after a dose. It is not for people with uncontrolled high blood pressure or heart disease, and it is not approved for men.
When it showed up, in studies
Blood pressure rises for a few hours after.
Desire scores improved over 24 weeks.
Sources
Put this grade on your site
Copy the line below. The badge links back to this page, so readers can check the sources. It grades the compound in studies. It does not rate any product or seller.
<a href="https://www.workedinrats.com/compounds/pt-141-bremelanotide"><img src="https://www.workedinrats.com/badge/pt-141-bremelanotide.svg" alt="PT-141 (bremelanotide): grade A, strong human proof. Worked in Rats" width="300" height="72"></a>
Keep going
We show what studies found. We never tell you what to take. Doses vary by study. Check the sources and talk to a doctor.